Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis.
However, their aberrant overexpression and glycosylation in various malignancies facilitate …

The aim of this review is to integrate non-exhaustive relevant data on the phenotype of
human plasma cells (PC), including normal, reactive and malignant (multiple myeloma, MM) …

Abstract The IUPAC (International Union of Pure and Applied Chemistry) Periodic Table of
the Elements and Isotopes (IPTEI) was created to familiarize students, teachers, and non …

In lymphoid malignancies and in certain solid cancers such as medullary thyroid carcinoma,
somewhat mixed success has been achieved when applying radioimmunotherapy (RIT) with …

The inability of the immune system to recognize and kill malignant plasma cells in patients
with multiple myeloma (MM) has been attributed in part to the ineffective activation of natural …

The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has
markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated …

The clinical efficacy of the first approved alpha pharmaceutical, Xofigo (radium-223
dichloride, 223RaCl2), has stimulated significant interest in the development of new alpha …

We tested the in vitro and in vivo antitumor activity of the maytansinoid DM1 (N2′-deacetyl-
N2′-(3-mercapto-1-oxopropyl)-maytansine), a potent antimicrotubule agent, covalently …

The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the
past decade with the discovery and validation of proteasome inhibitors and …

We present the synthesis and characterization of a highly efficient thorium chelator, derived
from the octadentate hydroxypyridinone class of compounds. The chelator forms extremely …